Fig. 1
From: Validation of a novel model for the early detection of hepatocellular carcinoma
Concentrations of biomarkers for each study subject in the development cohort (JHMI/UTSMC) and validation cohort (NCI EDRN). a AFP concentration in the development cohort; b PIVKA-II concentration in the development cohort; c probability of HCC detection in the development cohort (no cancer = 0, cancer = 1); d AFP concentration in the validation cohort; (E) PIVKA-II concentration in the validation cohort; f probability of HCC detection in the validation cohort (cirrhosis vs. cancer)